ABCL logo

AbCellera Biologics (ABCL)

Profile

Full Name

AbCellera Biologics Inc.

Ticker Symbol

ABCL

Exchange

NASDAQ

Country

Canada

IPO

December 11, 2020

Indexes

Not included

Employees

596

Key Details

Price

$2.43(-0.41%)

Market cap

$724.11M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$28.83M(-24.17% YoY)

Annual EPS

-$0.55(-7.84% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 3, 25 Benchmark
Hold
Feb 28, 25 Stifel
Buy
Jan 8, 25 Keybanc
Overweight
Nov 5, 24 Stifel
Buy
Nov 5, 24 Benchmark
Hold
Aug 20, 24 Benchmark
Hold
Jul 11, 24 Keybanc
Overweight
May 8, 24 Keybanc
Overweight
Feb 22, 24 Benchmark
Buy
Feb 21, 24 Stifel
Buy

Institutional Ownership

  • What is the ticker symbol for AbCellera Biologics?
  • Does AbCellera Biologics pay dividends?
  • What sector is AbCellera Biologics in?
  • What industry is AbCellera Biologics in?
  • What country is AbCellera Biologics based in?
  • When did AbCellera Biologics go public?
  • Is AbCellera Biologics in the S&P 500?
  • Is AbCellera Biologics in the NASDAQ 100?
  • Is AbCellera Biologics in the Dow Jones?
  • When was AbCellera Biologics's last earnings report?
  • When does AbCellera Biologics report earnings?
  • Should I buy AbCellera Biologics stock now?

What is the ticker symbol for AbCellera Biologics?

The ticker symbol for AbCellera Biologics is NASDAQ:ABCL

Does AbCellera Biologics pay dividends?

No, AbCellera Biologics does not pay dividends

What sector is AbCellera Biologics in?

AbCellera Biologics is in the Healthcare sector

What industry is AbCellera Biologics in?

AbCellera Biologics is in the Biotechnology industry

What country is AbCellera Biologics based in?

AbCellera Biologics is headquartered in Canada

When did AbCellera Biologics go public?

AbCellera Biologics's initial public offering (IPO) was on December 11, 2020

Is AbCellera Biologics in the S&P 500?

No, AbCellera Biologics is not included in the S&P 500 index

Is AbCellera Biologics in the NASDAQ 100?

No, AbCellera Biologics is not included in the NASDAQ 100 index

Is AbCellera Biologics in the Dow Jones?

No, AbCellera Biologics is not included in the Dow Jones index

When was AbCellera Biologics's last earnings report?

AbCellera Biologics's most recent earnings report was on Feb 27, 2025

When does AbCellera Biologics report earnings?

The next expected earnings date for AbCellera Biologics is May 8, 2025

Should I buy AbCellera Biologics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page